HopeStage
Back to all studies
CompletedNCT02507206

DAR-0100A for Attention and Memory in Schizotypal Personality

About this titleRead the official source — NCT02507206
Medication studyAges 18–65United StatesPersonality disorders
The study in practice

Understand this study

Who was this study for?

Listed age limits: 18 years to 65 years.

Listed locations
New YorkSee all locations and recruitment
Study phase
Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.

Get this study by email

HopeStage may email me about this study.
Loading the security check...
Study clarity

Study information

Study start dateApril 2013
Recruitment status
Completed
Enrollment listed in the registry
120
Sponsor
Antonia New
Sponsor type
Unknown or unclear
Study type
Drug
Intervention type
Drug
Study phase
Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
Locations
United States
Age range
From 18 Years to 65 Years
Official registry ID
NCT02507206
Official title
Show the full official title

A D1 Agonist For Working Memory Enhancement In The Schizophrenia Spectrum

Looking for a study you can join?

Explore recruiting studies

Recruitment & locations

Completed

New York

Registry details
Registry conditions (original wording)

Schizotypal Personality Disorder; SPD

Interested in joining this study?

HopeStage may email me about this study.
Loading the security check...
FAQ

Questions about this study

Who is behind this study?

The study sponsor is Antonia New.

Did this study involve medication?

Yes. The study involved medication, including DAR 0-100A and Placebo.

Who was this study for?

Listed age limits: 18 years to 65 years.

Want to explore more studies?

Explore studies